trending Market Intelligence /marketintelligence/en/news-insights/trending/_D_W9o1no2j3mHI3KaEm4w2 content esgSubNav
In This List

Karyopharm's Selinexor granted speedy review from EU regulator

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Karyopharm's Selinexor granted speedy review from EU regulator

Karyopharm Therapeutics Inc. has applied to market its medicine Selinexor, which treats a highly resistant form of blood cancer, with the European Medicines Agency.

The Newton, Mass.-based company is seeking approval for Selinexor in patients with refractory multiple myeloma whose disease has not responded to three prior treatments. Multiple myeloma occurs when plasma cells, found in the bone marrow, become cancerous and grow out of control.

The application is based on positive results from a phase 2 trial named Storm, which found that Selinexor shrank tumors in patients with the aggressive blood cancer.

Karyopharm Therapeutics said the European Medicines Agency's Committee for Medicinal Products for Human Use has granted accelerated assessment to Selinexor, which could reduce review time of the marketing authorization application to 150 days from the standard 210 days.

The U.S. Food and Drug Administration has granted a priority review to Selinexor for the same type of cancer and has set a decision date of April 6.